# CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

> **NCT06208735** · PHASE1 · RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 24 (estimated)

## Conditions studied

- B-Cell Leukemia
- Non-Hodgkin's Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Mantle Cell Lymphoma
- B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** CLIC-2201

## Key facts

- **NCT ID:** NCT06208735
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-02
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208735, "CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06208735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*